European Journal of Cancer
Volume 46, Issue 4 , Pages 818-825 , March 2010

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis

  • Adam J.W. Paige

      Affiliations

    • Ovarian cancer action (HHMT) Research Centre and Section of Molecular Therapeutics, Department of Oncology, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom
    • Corresponding Author InformationCorresponding author: Tel.: +44 207 594 1548; fax: +44 207 594 2129.
    • ,
  • Manuela Zucknick

      Affiliations

    • Centre for Biostatistics, Department of Epidemiology and Public Health, Imperial College London St. Mary’s Campus, London, United Kingdom
    • Department of Biostatistics, German Cancer Research Centre, Heidelberg, Germany
    • ,
  • Szymon Janczar

      Affiliations

    • Ovarian cancer action (HHMT) Research Centre and Section of Molecular Therapeutics, Department of Oncology, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom
    • ,
  • Jim Paul

      Affiliations

    • Clinical Trials Unit, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    • ,
  • Charles A. Mein

      Affiliations

    • Genome Centre, Institute of Cancer and the CR-UK Clinical Centre, Barts and the London, Queen Mary’s School of Dentistry and Medicine, London, United Kingdom
    • ,
  • Karen J. Taylor

      Affiliations

    • Cancer Research UK and University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
    • ,
  • Moira Stewart

      Affiliations

    • Cancer Research UK and University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
    • ,
  • Charlie Gourley

      Affiliations

    • Cancer Research UK and University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
    • ,
  • Sylvia Richardson

      Affiliations

    • Centre for Biostatistics, Department of Epidemiology and Public Health, Imperial College London St. Mary’s Campus, London, United Kingdom
    • ,
  • Timothy Perren

      Affiliations

    • CRUK Clinical Centre, St James’s University Hospital, Leeds, United Kingdom
    • ,
  • Trivadi S. Ganesan

      Affiliations

    • Cancer Institute and Institute of Molecular Medicine, Amrita Institute of Medical Sciences and Research Centre, Kochi, India
    • ,
  • John F. Smyth

      Affiliations

    • Cancer Research UK and University of Edinburgh Cancer Research Centre, Edinburgh, United Kingdom
    • ,
  • Robert Brown

      Affiliations

    • Ovarian cancer action (HHMT) Research Centre and Section of Molecular Therapeutics, Department of Oncology, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom
    • ,
  • Hani Gabra

      Affiliations

    • Ovarian cancer action (HHMT) Research Centre and Section of Molecular Therapeutics, Department of Oncology, Imperial College London Hammersmith Campus, Du Cane Road, London W12 0NN, United Kingdom

Received 2 December 2009 ,Accepted 14 December 2009.

References 

  1. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol. 2007;17:31–41
  2. McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, et al. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res. 2007;118:260–269
  3. Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletion of WWOX reveals a tumor suppressor function. Proc Natl Acad Sci USA. 2007;104:3949–3954
  4. Fujishita T, Doi Y, Sonoshita M, et al. Development of spontaneous tumours and intestinal lesions in Fhit gene knockout mice. Br J Cancer. 2004;91:1571–1574
  5. Bednarek AK, Keck-Waggoner CL, Daniel RL, et al. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 2001;61:8068–8073
  6. Fabbri M, Iliopoulos D, Trapasso F, et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci USA. 2005;102:15611–15616
  7. Gourley C, Paige AJ, Taylor KJ, et al. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res. 2009;69:4835–4842
  8. Chang NS, Pratt N, Heath J, et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem. 2001;276:3361–3370
  9. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res. 2000;60:2140–2145
  10. Paige AJW, Taylor KJ, Taylor C, et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA. 2001;98:11417–11422
  11. Iliopoulos D, Guler G, Han SY, et al. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene. 2005;24:1625–1633
  12. Wei SH, Balch C, Paik HH, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res. 2006;12:2788–2794
  13. Gourley C, Paige AJW, Taylor KJ, et al. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol. 2005;26:1681–1689
  14. Nunez MI, Rosen DG, Ludes-Meyers JH, et al. W.W.O.X. protein expression varies among ovarian carcinoma histotypes, correlates with less favorable outcome. BMC Cancer. 2005;5:64
  15. Garg R, Wollan M, Galic V, et al. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006;103:793–796
  16. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ. MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat. 2008;111:497–504
  17. Lange EM, Beebe-Dimmer JL, Ray AM, et al. Genome-wide linkage scan for prostate cancer susceptibility from the University of Michigan Prostate Cancer Genetics Project: suggestive evidence for linkage at 16q23. Prostate. 2009;69:385–391
  18. Murabito JM, Rosenberg CL, Finger D, et al. A genome-wide association study of breast and prostate cancer in the NHLBI’s Framingham Heart Study. BMC Med Genet. 2007;8(Suppl. 1):S6
  19. Marsh S, Paul J, King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol. 2007;25:4528–4535
  20. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682–1691
  21. Grambsch P, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–526
  22. Therneau T, Grambsch P, Fleming T. Martingale based residuals for survival models. Biometrika. 1990;77:147–160
  23. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681–694
  24. van Buuren S, Oudshoorn K. Flexible multivariate imputation by MICE. Leiden; 1999.
  25. Donati V, Fontanini G, Dell’Omodarme M, et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res. 2007;13:884–891
  26. Stranger BE, Nica AC, Forrest MS, et al. Population genomics of human gene e2cression. Nat Genet. 2007;39:1217–1224
  27. Pennacchio LA, Ahituv N, Moses AM, et al. In vivo enhancer analysis of human conserved non-coding sequences. Nature. 2006;444:499–502
  28. Lee JC, Weissglas-Volkov D, Kyttala M, et al. WW-domain-containing oxidoreductase is associated with low plasma HDL-C levels. Am J Hum Genet. 2008;83:180–192
  29. Pearce CL, Wu AH, Gayther SA, et al. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the ovarian cancer association consortium pooled analysis. Br J Cancer. 2008;98:282–288
  30. Ramus SJ, Vierkant RA, Johnatty SE, et al. Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer. 2008;123:380–388

PII: S0959-8049(09)00933-2

doi: 10.1016/j.ejca.2009.12.021

European Journal of Cancer
Volume 46, Issue 4 , Pages 818-825 , March 2010

Article Tools

* Image Usage & Resolution